LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase

Photo by enginakyurt from unsplash

Key Points • HDAC1 inhibition dampens IRF4 transcription through histone hyperacetylation, thereby reducing the expression of the survival mediator PIM2.• Simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated… Click to show full abstract

Key Points • HDAC1 inhibition dampens IRF4 transcription through histone hyperacetylation, thereby reducing the expression of the survival mediator PIM2.• Simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated PIM2 represents an efficient therapeutic option for MM.

Keywords: irf4 axis; therapeutic option; inhibition; hdac1 irf4

Journal Title: Blood Advances
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.